<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108262</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-HDL-12-77</org_study_id>
    <secondary_id>2013-003458-26</secondary_id>
    <nct_id>NCT02108262</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.</brief_title>
  <official_title>A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter randomized, double-blind, placebo-controlled, parallel-group,&#xD;
      dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of&#xD;
      multiple dose administration of two dose levels of CSL112 compared with placebo in subjects&#xD;
      with acute myocardial infarction (AMI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Clinically Important Change in Drug-induced Liver Injury</measure>
    <time_frame>From baseline (before first infusion) to Day 29.</time_frame>
    <description>A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With Clinically Important Change in Renal Status</measure>
    <time_frame>From baseline (before first infusion) to Day 29.</time_frame>
    <description>A clinically important change in renal status is defined as a serum creatinine (Cr) increase to ≥ 1.5 x the baseline value that is confirmed upon repeat measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Participants With a Time-to-first Major Adverse Cardiovascular Event (MACE)</measure>
    <time_frame>From the start of the first infusion up to approximately 382 days</time_frame>
    <description>The MACE is a 4-component composite comprised of the time to the first of the following events: CV death, nonfatal myocardial infarction, ischemic stroke (non-hemorrhagic), and hospitalization for unstable angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Concentrations of Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) at End of First Infusion for All Participants</measure>
    <time_frame>Before first infusion and end of first infusion</time_frame>
    <description>Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) are analytes of CSL112</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion and end of fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion and end of first infusion</time_frame>
    <description>apoA-I and PC are analytes of CSL112</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion and end of fourth infusion</time_frame>
    <description>apoA-I and PC are analytes of CSL112</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion and end of first infusion</time_frame>
    <description>apoA-I and PC are analytes of CSL112</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion and end of fourth infusion</time_frame>
    <description>apoA-I and PC are analytes of CSL112</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Cmax is the maximal plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before and for 7 days after the first infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before and for 7 days after the fourth infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before and for 7 days after the first infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before and for 7 days after the fourth infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before and for 7 days after the first infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before and for 7 days after the fourth infusion</time_frame>
    <description>Tmax is time to maximal plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Area Under the Curve (AUC) AUC0 - Last for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Subjects With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC from baseline to time point t (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
    <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Volume of Distribution at Steady State (Vss) for apoA-I and PC After First Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for All Participants</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</measure>
    <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With the Occurrence of Suspected Adverse Drug Reactions</measure>
    <time_frame>From the start of first infusion, up to approximately Day 382</time_frame>
    <description>The overall percentage of subjects:&#xD;
with adverse events (AEs), including local tolerability events, that begin during or within 1 hour of an infusion; or&#xD;
with AEs considered to be causally related to the test product; or&#xD;
who experience an AE for which the incidence rate in an active treatment arm exceeds the exposure-adjusted incidence rate in the placebo arm by 30% or more, provided the difference in incidence rates is 1% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Any Adverse Event (AE)</measure>
    <time_frame>From the start of first infusion, up to approximately Day 382</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Experience Bleeding Events</measure>
    <time_frame>From the start of first infusion, up to approximately Day 112</time_frame>
    <description>The number of subjects who experience bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria (Mehran et al, 2011)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Antibodies to CSL112 and apoA-I</measure>
    <time_frame>Before first infusion, up to approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Serology Results for IgG and IgM Antibodies to Parvovirus B19</measure>
    <time_frame>Study Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Parvovirus B19 DNA in Serum</measure>
    <time_frame>Study Day 112</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1267</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>CSL112 - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL112 - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL112</intervention_name>
    <description>CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
    <arm_group_label>CSL112 - high dose</arm_group_label>
    <arm_group_label>CSL112 - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, at least 18 years of age, with evidence of myocardial necrosis in a&#xD;
             clinical setting consistent with a type I (spontaneous) acute myocardial infarction&#xD;
             (AMI), in the last week.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing hemodynamic instability&#xD;
&#xD;
          -  Evidence of hepatobiliary disease&#xD;
&#xD;
          -  Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate or&#xD;
             severe renal impairment or if subject is receiving dialysis&#xD;
&#xD;
          -  Evidence of unstable renal function&#xD;
&#xD;
          -  History of acute kidney injury after previous exposure to an intravenous contrast&#xD;
             agent.&#xD;
&#xD;
          -  Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its&#xD;
             components&#xD;
&#xD;
          -  Other severe comorbid condition, concurrent medication, or other issue that renders&#xD;
             the subject unsuitable for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Denise D'Andrea</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site 16101</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16078</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 16168</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16168</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16147</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16022</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16130</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16170</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16135</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16148</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16003</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16144</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16112</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16060</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16179</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16102</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16025</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16088</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16004</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16016</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16208</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16062</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16079</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16031</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16028</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16061</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16211</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16234</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16063</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16033</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16174</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16213</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16056</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16201</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16014</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16024</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16047</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16026</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16100</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16017</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16039</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16018</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16202</name>
      <address>
        <city>Greeneville</city>
        <state>Tennessee</state>
        <zip>37745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16015</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16099</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16241</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16038</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 16166</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10002</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10005</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10012</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10006</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 10007</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11004</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11002</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 11001</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12005</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12008</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12006</name>
      <address>
        <city>Dobrich</city>
        <zip>9300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12021</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12009</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12019</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12016</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12014</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12018</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12017</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12003</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12001</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12004</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12012</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12010</name>
      <address>
        <city>Sofia</city>
        <zip>152</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12013</name>
      <address>
        <city>Sofia</city>
        <zip>1750</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12011</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12002</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 12007</name>
      <address>
        <city>Yambol</city>
        <zip>8600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13003</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13002</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13017</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 3G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13012</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13019</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13008</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13010</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13014</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 13007</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14010</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14006</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14004</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14012</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>466 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14011</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14016</name>
      <address>
        <city>Kolin</city>
        <zip>280 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14017</name>
      <address>
        <city>Nachod</city>
        <zip>547 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14007</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14003</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14002</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14001</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14015</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14008</name>
      <address>
        <city>Praha 4 - Krc</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14009</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14014</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 14005</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15001</name>
      <address>
        <city>Alborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15005</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15002</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15004</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 15003</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25003</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25005</name>
      <address>
        <city>Toulouse cedex 3</city>
        <state>Haute Garonne</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25008</name>
      <address>
        <city>Nantes cedex</city>
        <state>Loire Antlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25002</name>
      <address>
        <city>Paris cedex 12</city>
        <state>Paris</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25004</name>
      <address>
        <city>Pau</city>
        <state>Pyrenees Atlantiques</state>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 25001</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17001</name>
      <address>
        <city>Freiburg</city>
        <state>Baden Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17005</name>
      <address>
        <city>Berlin</city>
        <state>Berin</state>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17014</name>
      <address>
        <city>Franfurt</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17012</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17007</name>
      <address>
        <city>Luedenscheid</city>
        <state>Nordrhein Westfalen</state>
        <zip>58509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17010</name>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland Pfalz</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17011</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17003</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17009</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17002</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 17006</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18008</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18001</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18005</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18002</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18007</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18003</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18009</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 18006</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19010</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19006</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19005</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19004</name>
      <address>
        <city>Holon</city>
        <zip>5822012</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19003</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19007</name>
      <address>
        <city>Jerusalem</city>
        <zip>9124001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19002</name>
      <address>
        <city>Nahariya</city>
        <zip>2210001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19009</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 19008</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20003</name>
      <address>
        <city>Legnano</city>
        <state>Milano</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20002</name>
      <address>
        <city>Magenta</city>
        <state>Milano</state>
        <zip>20013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20008</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20009</name>
      <address>
        <city>Benevento</city>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20011</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20007</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20012</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20001</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 20006</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21001</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21006</name>
      <address>
        <city>Amsterdam</city>
        <zip>091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21013</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21016</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21004</name>
      <address>
        <city>Ede</city>
        <zip>6716 RP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21014</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21003</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21008</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21009</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21010</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21015</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 21011</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22015</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22010</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22012</name>
      <address>
        <city>Inowroclaw</city>
        <zip>88-10</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 22009</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22007</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22014</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22013</name>
      <address>
        <city>Starogard Gdanski</city>
        <zip>83-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22006</name>
      <address>
        <city>Walbrzych</city>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22008</name>
      <address>
        <city>Warszawa</city>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22016</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 22005</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23010</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23012</name>
      <address>
        <city>A Coruna</city>
        <state>La Coruna</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23006</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23005</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23002</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23001</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23003</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23013</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23004</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23007</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23009</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 23011</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24006</name>
      <address>
        <city>Clydebank</city>
        <state>Dunbartonshire</state>
        <zip>G81 1DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24004</name>
      <address>
        <city>Basildon</city>
        <state>Essex</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site 24005</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <zip>UM7 0AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24003</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24010</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site - 24009</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <results_first_submitted>January 20, 2021</results_first_submitted>
  <results_first_submitted_qc>February 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <disposition_first_submitted>December 13, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 13, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 14, 2016</disposition_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Safety Lead-in [CSL112 (2 g)]</title>
          <description>In the safety lead-in, a small number of subjects (evenly stratified between subjects with normal renal function or mild renal impairment) were administered a single, 2 g infusion of CSL112.</description>
        </group>
        <group group_id="P2">
          <title>CSL112 (2 g)</title>
          <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
        </group>
        <group group_id="P3">
          <title>CSL112 (6 g)</title>
          <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="421"/>
                <participants group_id="P4" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="375"/>
                <participants group_id="P3" count="379"/>
                <participants group_id="P4" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized by error/screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Distance to center</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to key hepatic values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to contact patient</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient unable to come to site/attend visit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient did not want another infusion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vacation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed IV due to pharmacy error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Safety Lead-in [CSL112 (2 g)]</title>
          <description>In the safety lead-in, a small number of subjects (evenly stratified between subjects with normal renal function or mild renal impairment) were administered a single, 2 g infusion of CSL112.</description>
        </group>
        <group group_id="B2">
          <title>CSL112 (2 g)</title>
          <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
        </group>
        <group group_id="B3">
          <title>CSL112 (6 g)</title>
          <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="419"/>
            <count group_id="B3" value="421"/>
            <count group_id="B4" value="418"/>
            <count group_id="B5" value="1267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="301"/>
                    <measurement group_id="B5" value="910"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="7.19"/>
                    <measurement group_id="B2" value="57.7" spread="10.15"/>
                    <measurement group_id="B3" value="59.2" spread="9.87"/>
                    <measurement group_id="B4" value="58.1" spread="10.57"/>
                    <measurement group_id="B5" value="58.3" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="323"/>
                    <measurement group_id="B4" value="341"/>
                    <measurement group_id="B5" value="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Renal function from Interactive Web Response System (IWRS)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal renal function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="191"/>
                    <measurement group_id="B5" value="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild renal impairment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="227"/>
                    <measurement group_id="B5" value="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Clinically Important Change in Drug-induced Liver Injury</title>
        <description>A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.</description>
        <time_frame>From baseline (before first infusion) to Day 29.</time_frame>
        <population>The Safety population (SP) comprised all subjects who were randomized into the main study or PK/PD substudy and received at least a partial infusion of the investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Clinically Important Change in Drug-induced Liver Injury</title>
          <description>A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.</description>
          <population>The Safety population (SP) comprised all subjects who were randomized into the main study or PK/PD substudy and received at least a partial infusion of the investigational product.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The calculation used a non-inferiority argument powering the test of the alternative hypothesis of no difference in the rates. Within each co-primary endpoint, the two active treatment groups are assumed to have the same endpoint rates. Total alpha is 0.05 with 0.025 allocated to each co-primary endpoint, which in turn involves comparisons of two active treatment groups to placebo without further alpha control.</non_inferiority_desc>
            <p_value>= 0.1241</p_value>
            <method>Newcombe-Wilson score method</method>
            <param_type>Difference in event rates (%)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The calculation used a non-inferiority argument powering the test of the alternative hypothesis of no difference in the rates. Within each co-primary endpoint, the two active treatment groups are assumed to have the same endpoint rates. Total alpha is 0.05 with 0.025 allocated to each co-primary endpoint, which in turn involves comparisons of two active treatment groups to placebo without further alpha control.</non_inferiority_desc>
            <p_value>= 0.4994</p_value>
            <method>Newcombe-Wilson score method</method>
            <param_type>Difference in event rates (%)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Clinically Important Change in Renal Status</title>
        <description>A clinically important change in renal status is defined as a serum creatinine (Cr) increase to ≥ 1.5 x the baseline value that is confirmed upon repeat measurement.</description>
        <time_frame>From baseline (before first infusion) to Day 29.</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Clinically Important Change in Renal Status</title>
          <description>A clinically important change in renal status is defined as a serum creatinine (Cr) increase to ≥ 1.5 x the baseline value that is confirmed upon repeat measurement.</description>
          <population>SP</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The calculation used a non-inferiority argument powering the test of the alternative hypothesis of no difference in the rates. Within each co-primary endpoint, the two active treatment groups are assumed to have the same endpoint rates. Total alpha is 0.05 with 0.025 allocated to each co-primary endpoint, which in turn involves comparisons of two active treatment groups to placebo without further alpha control.</non_inferiority_desc>
            <p_value>= 0.4988</p_value>
            <method>Newcombe-Wilson score method</method>
            <param_type>Difference in event rates (%)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The calculation used a non-inferiority argument powering the test of the alternative hypothesis of no difference in the rates. Within each co-primary endpoint, the two active treatment groups are assumed to have the same endpoint rates. Total alpha is 0.05 with 0.025 allocated to each co-primary endpoint, which in turn involves comparisons of two active treatment groups to placebo without further alpha control.</non_inferiority_desc>
            <p_value>= 0.6241</p_value>
            <method>Newcombe-Wilson score method</method>
            <param_type>Difference in event rates (%)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Participants With a Time-to-first Major Adverse Cardiovascular Event (MACE)</title>
        <description>The MACE is a 4-component composite comprised of the time to the first of the following events: CV death, nonfatal myocardial infarction, ischemic stroke (non-hemorrhagic), and hospitalization for unstable angina.</description>
        <time_frame>From the start of the first infusion up to approximately 382 days</time_frame>
        <population>The Intent-to-Treat (ITT) population comprised all subjects who were randomized to one of the three treatment groups for the Main Study or PK/PD substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants With a Time-to-first Major Adverse Cardiovascular Event (MACE)</title>
          <description>The MACE is a 4-component composite comprised of the time to the first of the following events: CV death, nonfatal myocardial infarction, ischemic stroke (non-hemorrhagic), and hospitalization for unstable angina.</description>
          <population>The Intent-to-Treat (ITT) population comprised all subjects who were randomized to one of the three treatment groups for the Main Study or PK/PD substudy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.5733</p_value>
            <p_value_desc>Stratified log-rank p-value</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>= 0.9717</p_value>
            <p_value_desc>Stratified log-rank p-value</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Concentrations of Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) at End of First Infusion for All Participants</title>
        <description>Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) are analytes of CSL112</description>
        <time_frame>Before first infusion and end of first infusion</time_frame>
        <population>The pharmacokinetic population (PK) comprised all subjects who received at least 1 infusion of investigational product and had at least 1 post baseline measurable plasma concentration of apoA-I or PC.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Concentrations of Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) at End of First Infusion for All Participants</title>
          <description>Apolipoprotein A-I (apoA-I) and Phosphatidylcholine (PC) are analytes of CSL112</description>
          <population>The pharmacokinetic population (PK) comprised all subjects who received at least 1 infusion of investigational product and had at least 1 post baseline measurable plasma concentration of apoA-I or PC.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="404"/>
                <count group_id="O3" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="22.13"/>
                    <measurement group_id="O2" value="136.1" spread="54.37"/>
                    <measurement group_id="O3" value="-4.7" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7" spread="31.12"/>
                    <measurement group_id="O2" value="180.4" spread="74.4"/>
                    <measurement group_id="O3" value="-1.2" spread="20.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for All Participants</title>
        <time_frame>Before first infusion and end of fourth infusion</time_frame>
        <population>PK</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for All Participants</title>
          <population>PK</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="55.03"/>
                    <measurement group_id="O2" value="158.0" spread="55.07"/>
                    <measurement group_id="O3" value="5.4" spread="26.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="55.75"/>
                    <measurement group_id="O2" value="186.8" spread="79.39"/>
                    <measurement group_id="O3" value="-12.9" spread="42.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Normal Renal Function</title>
        <description>apoA-I and PC are analytes of CSL112</description>
        <time_frame>Before first infusion and end of first infusion</time_frame>
        <population>PK</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Normal Renal Function</title>
          <description>apoA-I and PC are analytes of CSL112</description>
          <population>PK</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="25.35"/>
                    <measurement group_id="O2" value="134.5" spread="48.25"/>
                    <measurement group_id="O3" value="-4.0" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0" spread="37.06"/>
                    <measurement group_id="O2" value="177.4" spread="67.93"/>
                    <measurement group_id="O3" value="-1.3" spread="25.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Normal Renal Function</title>
        <description>apoA-I and PC are analytes of CSL112</description>
        <time_frame>Before first infusion and end of fourth infusion</time_frame>
        <population>PK</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Normal Renal Function</title>
          <description>apoA-I and PC are analytes of CSL112</description>
          <population>PK</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="74.94"/>
                    <measurement group_id="O2" value="154.3" spread="53.64"/>
                    <measurement group_id="O3" value="4.8" spread="28.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="64.67"/>
                    <measurement group_id="O2" value="182.0" spread="80.74"/>
                    <measurement group_id="O3" value="-12.3" spread="44.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Mild Renal Impairment</title>
        <description>apoA-I and PC are analytes of CSL112</description>
        <time_frame>Before first infusion and end of first infusion</time_frame>
        <population>PK</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of First Infusion for Participants With Mild Renal Impairment</title>
          <description>apoA-I and PC are analytes of CSL112</description>
          <population>PK</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="19.05"/>
                    <measurement group_id="O2" value="135.5" spread="59.05"/>
                    <measurement group_id="O3" value="-5.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" spread="24.71"/>
                    <measurement group_id="O2" value="180.6" spread="79.50"/>
                    <measurement group_id="O3" value="-0.8" spread="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>apoA-I and PC are analytes of CSL112</description>
        <time_frame>Before first infusion and end of fourth infusion</time_frame>
        <population>PK</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Concentrations of apoA-I and PC at End of Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>apoA-I and PC are analytes of CSL112</description>
          <population>PK</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="27.63"/>
                    <measurement group_id="O2" value="158.4" spread="56.19"/>
                    <measurement group_id="O3" value="6.0" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="47.17"/>
                    <measurement group_id="O2" value="188.3" spread="79.39"/>
                    <measurement group_id="O3" value="-13.2" spread="40.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for All Participants</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>The Pharmacokinetic/Pharmacodynamic (PK/PD) population was a subset of subjects from the main study who consented to participate in the PK/PD substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for All Participants</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>The Pharmacokinetic/Pharmacodynamic (PK/PD) population was a subset of subjects from the main study who consented to participate in the PK/PD substudy.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="11.2"/>
                    <measurement group_id="O2" value="147.4" spread="31.9"/>
                    <measurement group_id="O3" value="7.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="19.2"/>
                    <measurement group_id="O2" value="196.4" spread="36.2"/>
                    <measurement group_id="O3" value="11.1" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for All Participants</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for All Participants</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>PK/PD</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="19.5"/>
                    <measurement group_id="O2" value="164.3" spread="33.4"/>
                    <measurement group_id="O3" value="12.7" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="34.2"/>
                    <measurement group_id="O2" value="187.4" spread="49.9"/>
                    <measurement group_id="O3" value="9.1" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>PK/PD</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" spread="12.0"/>
                    <measurement group_id="O2" value="135.1" spread="22.8"/>
                    <measurement group_id="O3" value="7.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="21.0"/>
                    <measurement group_id="O2" value="184.9" spread="31.5"/>
                    <measurement group_id="O3" value="13.0" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>PK/PD</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="19.2"/>
                    <measurement group_id="O2" value="149.0" spread="26.9"/>
                    <measurement group_id="O3" value="17.5" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="26.4"/>
                    <measurement group_id="O2" value="176.1" spread="54.0"/>
                    <measurement group_id="O3" value="20.1" spread="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>PK/PD</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="10.2"/>
                    <measurement group_id="O2" value="160.7" spread="37.0"/>
                    <measurement group_id="O3" value="5.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="14.7"/>
                    <measurement group_id="O2" value="211.3" spread="37.5"/>
                    <measurement group_id="O3" value="6.0" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>Cmax is the maximal plasma concentration.</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Cmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>Cmax is the maximal plasma concentration.</description>
          <population>PK/PD</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="20.1"/>
                    <measurement group_id="O2" value="169.7" spread="29.3"/>
                    <measurement group_id="O3" value="1.0" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="37.0"/>
                    <measurement group_id="O2" value="190.4" spread="46.7"/>
                    <measurement group_id="O3" value="-17.4" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for All Participants</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for All Participants</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" lower_limit="1.7" upper_limit="236.9"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="46.8" lower_limit="0" upper_limit="216.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O3" value="5.29" lower_limit="0" upper_limit="188.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for All Participants</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for All Participants</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="2" upper_limit="23.5"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2" upper_limit="4.2"/>
                    <measurement group_id="O3" value="119" lower_limit="0" upper_limit="332.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2" upper_limit="53.1"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2" upper_limit="4.2"/>
                    <measurement group_id="O3" value="46.93" lower_limit="0" upper_limit="187.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.7" upper_limit="236.9"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="3.4"/>
                    <measurement group_id="O3" value="96.1" lower_limit="0" upper_limit="216.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" lower_limit="1.7" upper_limit="8.4"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="3.4"/>
                    <measurement group_id="O3" value="8.1" lower_limit="0" upper_limit="188.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="2.1" upper_limit="3.5"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="2.4"/>
                    <measurement group_id="O3" value="119.3" lower_limit="0" upper_limit="332.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2.1" upper_limit="53.1"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2" upper_limit="2.4"/>
                    <measurement group_id="O3" value="29" lower_limit="0" upper_limit="187.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" lower_limit="2.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.22" lower_limit="2.1" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="117.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" lower_limit="2.1" upper_limit="5"/>
                    <measurement group_id="O2" value="2.22" lower_limit="2.1" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>Tmax is time to maximal plasma concentration</description>
        <time_frame>Before and for 7 days after the fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Tmax for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>Tmax is time to maximal plasma concentration</description>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2" upper_limit="23.5"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="72.5" lower_limit="0" upper_limit="166.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2.1" upper_limit="4.2"/>
                    <measurement group_id="O3" value="48.3" lower_limit="9" upper_limit="166.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Area Under the Curve (AUC) AUC0 - Last for apoA-I and PC After First Infusion for All Participants</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Area Under the Curve (AUC) AUC0 - Last for apoA-I and PC After First Infusion for All Participants</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1703" spread="2149"/>
                    <measurement group_id="O2" value="4819" spread="2580"/>
                    <measurement group_id="O3" value="-766" spread="2248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.12" spread="3653"/>
                    <measurement group_id="O2" value="869" spread="3796"/>
                    <measurement group_id="O3" value="-2096" spread="3372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for All Participants</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for All Participants</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4579" spread="2705"/>
                    <measurement group_id="O2" value="8985" spread="4263"/>
                    <measurement group_id="O3" value="747" spread="3226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" spread="5327"/>
                    <measurement group_id="O2" value="2499" spread="7662"/>
                    <measurement group_id="O3" value="-2185" spread="5189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1278" spread="1742"/>
                    <measurement group_id="O2" value="3762" spread="2367"/>
                    <measurement group_id="O3" value="-516" spread="2091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1382" spread="2853"/>
                    <measurement group_id="O2" value="-137" spread="4057"/>
                    <measurement group_id="O3" value="-1337" spread="2590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4513" spread="2701"/>
                    <measurement group_id="O2" value="8609" spread="4500"/>
                    <measurement group_id="O3" value="1632" spread="3235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2130" spread="4691"/>
                    <measurement group_id="O2" value="3609" spread="10232"/>
                    <measurement group_id="O3" value="-542" spread="4480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Subjects With Mild Renal Impairment</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After First Infusion for Subjects With Mild Renal Impairment</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2205" spread="2543"/>
                    <measurement group_id="O2" value="5917" spread="2568"/>
                    <measurement group_id="O3" value="-1416" spread="2763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1489" spread="4003"/>
                    <measurement group_id="O2" value="1828" spread="3661"/>
                    <measurement group_id="O3" value="-4068" spread="4634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0 - Last for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>Area under the plasma concentration time curve (AUC) from time point zero (baseline) to the last quantifiable time-point before the analyte first returns to baseline [AUC0 - last]</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4659" spread="2854"/>
                    <measurement group_id="O2" value="8786" spread="4201"/>
                    <measurement group_id="O3" value="-1376" spread="2205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2712" spread="5010"/>
                    <measurement group_id="O2" value="1541" spread="5815"/>
                    <measurement group_id="O3" value="-6128" spread="4998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for All Participants</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for All Participants</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496" spread="212"/>
                    <measurement group_id="O2" value="1929" spread="557"/>
                    <measurement group_id="O3" value="-168" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="731" spread="447"/>
                    <measurement group_id="O2" value="2903" spread="944"/>
                    <measurement group_id="O3" value="-331" spread="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="880" spread="726"/>
                    <measurement group_id="O2" value="3516" spread="1248"/>
                    <measurement group_id="O3" value="-439" spread="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1006" spread="1104"/>
                    <measurement group_id="O2" value="3943" spread="1581"/>
                    <measurement group_id="O3" value="-541" spread="940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1009" spread="1761"/>
                    <measurement group_id="O2" value="4734" spread="2382"/>
                    <measurement group_id="O3" value="-452" spread="1498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508" spread="349"/>
                    <measurement group_id="O2" value="1545" spread="552"/>
                    <measurement group_id="O3" value="-92" spread="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466" spread="744"/>
                    <measurement group_id="O2" value="1627" spread="872"/>
                    <measurement group_id="O3" value="-315" spread="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418" spread="1251"/>
                    <measurement group_id="O2" value="1713" spread="1209"/>
                    <measurement group_id="O3" value="-549" spread="886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389" spread="1841"/>
                    <measurement group_id="O2" value="1712" spread="1694"/>
                    <measurement group_id="O3" value="-780" spread="1346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-405" spread="3636"/>
                    <measurement group_id="O2" value="1273" spread="2764"/>
                    <measurement group_id="O3" value="-1494" spread="2501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for All Participants</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for All Participants</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881" spread="422"/>
                    <measurement group_id="O2" value="2392" spread="655"/>
                    <measurement group_id="O3" value="-57" spread="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1593" spread="798"/>
                    <measurement group_id="O2" value="3913" spread="1235"/>
                    <measurement group_id="O3" value="-55" spread="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2195" spread="1177"/>
                    <measurement group_id="O2" value="5050" spread="1794"/>
                    <measurement group_id="O3" value="-6" spread="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2741" spread="1526"/>
                    <measurement group_id="O2" value="6000" spread="2292"/>
                    <measurement group_id="O3" value="90" spread="1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3997" spread="2655"/>
                    <measurement group_id="O2" value="8865" spread="3200"/>
                    <measurement group_id="O3" value="1635" spread="3540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" spread="681"/>
                    <measurement group_id="O2" value="1564" spread="1051"/>
                    <measurement group_id="O3" value="-488" spread="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472" spread="1293"/>
                    <measurement group_id="O2" value="1765" spread="1948"/>
                    <measurement group_id="O3" value="-902" spread="1433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509" spread="1989"/>
                    <measurement group_id="O2" value="1899" spread="2823"/>
                    <measurement group_id="O3" value="-1173" spread="2168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" spread="2679"/>
                    <measurement group_id="O2" value="1951" spread="3681"/>
                    <measurement group_id="O3" value="-1417" spread="2894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-625" spread="4963"/>
                    <measurement group_id="O2" value="2655" spread="6024"/>
                    <measurement group_id="O3" value="-442" spread="6319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418" spread="117"/>
                    <measurement group_id="O2" value="1653" spread="496"/>
                    <measurement group_id="O3" value="-149" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547" spread="204"/>
                    <measurement group_id="O2" value="2521" spread="955"/>
                    <measurement group_id="O3" value="-316" spread="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628" spread="337"/>
                    <measurement group_id="O2" value="3064" spread="1280"/>
                    <measurement group_id="O3" value="-435" spread="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="692" spread="554"/>
                    <measurement group_id="O2" value="3342" spread="1642"/>
                    <measurement group_id="O3" value="-528" spread="883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="821" spread="1387"/>
                    <measurement group_id="O2" value="3780" spread="2353"/>
                    <measurement group_id="O3" value="-275" spread="1461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364" spread="245"/>
                    <measurement group_id="O2" value="1347" spread="661"/>
                    <measurement group_id="O3" value="-46" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" spread="536"/>
                    <measurement group_id="O2" value="1294" spread="1025"/>
                    <measurement group_id="O3" value="-235" spread="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38" spread="946"/>
                    <measurement group_id="O2" value="1325" spread="1421"/>
                    <measurement group_id="O3" value="-426" spread="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-256" spread="1415"/>
                    <measurement group_id="O2" value="1218" spread="2005"/>
                    <measurement group_id="O3" value="-569" spread="1162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1511" spread="3053"/>
                    <measurement group_id="O2" value="437" spread="2061"/>
                    <measurement group_id="O3" value="-1089" spread="2188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="929" spread="396"/>
                    <measurement group_id="O2" value="2098" spread="463"/>
                    <measurement group_id="O3" value="20" spread="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1668" spread="753"/>
                    <measurement group_id="O2" value="3459" spread="1001"/>
                    <measurement group_id="O3" value="105" spread="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2252" spread="1116"/>
                    <measurement group_id="O2" value="4497" spread="1478"/>
                    <measurement group_id="O3" value="249" spread="1232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2769" spread="1473"/>
                    <measurement group_id="O2" value="5360" spread="1909"/>
                    <measurement group_id="O3" value="459" spread="1666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3811" spread="2706"/>
                    <measurement group_id="O2" value="8342" spread="2549"/>
                    <measurement group_id="O3" value="2486" spread="2804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="483"/>
                    <measurement group_id="O2" value="1524" spread="1388"/>
                    <measurement group_id="O3" value="-295" spread="819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" spread="952"/>
                    <measurement group_id="O2" value="1796" spread="2613"/>
                    <measurement group_id="O3" value="-523" spread="1446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-306" spread="1544"/>
                    <measurement group_id="O2" value="2000" spread="3773"/>
                    <measurement group_id="O3" value="-605" spread="2133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-573" spread="2204"/>
                    <measurement group_id="O2" value="2078" spread="4905"/>
                    <measurement group_id="O3" value="-633" spread="2772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3853" spread="3242"/>
                    <measurement group_id="O2" value="4584" spread="7822"/>
                    <measurement group_id="O3" value="1253" spread="4446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589" spread="263"/>
                    <measurement group_id="O2" value="2219" spread="515"/>
                    <measurement group_id="O3" value="-218" spread="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="949" spread="560"/>
                    <measurement group_id="O2" value="3308" spread="847"/>
                    <measurement group_id="O3" value="-370" spread="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1179" spread="946"/>
                    <measurement group_id="O2" value="3998" spread="1152"/>
                    <measurement group_id="O3" value="-451" spread="834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1376" spread="1468"/>
                    <measurement group_id="O2" value="4517" spread="1465"/>
                    <measurement group_id="O3" value="-576" spread="1188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1196" spread="2155"/>
                    <measurement group_id="O2" value="5624" spread="2293"/>
                    <measurement group_id="O3" value="-865" spread="1824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678" spread="386"/>
                    <measurement group_id="O2" value="1777" spread="353"/>
                    <measurement group_id="O3" value="-212" spread="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="845" spread="797"/>
                    <measurement group_id="O2" value="1968" spread="623"/>
                    <measurement group_id="O3" value="-523" spread="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956" spread="1393"/>
                    <measurement group_id="O2" value="2093" spread="950"/>
                    <measurement group_id="O3" value="-871" spread="1196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1227" spread="2058"/>
                    <measurement group_id="O2" value="2194" spread="1351"/>
                    <measurement group_id="O3" value="-1329" spread="1769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018" spread="4052"/>
                    <measurement group_id="O2" value="2004" spread="3214"/>
                    <measurement group_id="O3" value="2203" spread="3197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>AUC from baseline to time point t (AUC0-t)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-t for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>AUC from baseline to time point t (AUC0-t)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823" spread="466"/>
                    <measurement group_id="O2" value="2469" spread="573"/>
                    <measurement group_id="O3" value="-243" spread="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1503" spread="881"/>
                    <measurement group_id="O2" value="4049" spread="1221"/>
                    <measurement group_id="O3" value="-440" spread="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2128" spread="1304"/>
                    <measurement group_id="O2" value="5226" spread="1910"/>
                    <measurement group_id="O3" value="-617" spread="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2707" spread="1669"/>
                    <measurement group_id="O2" value="6212" spread="2503"/>
                    <measurement group_id="O3" value="-796" spread="1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>apoA-I (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4229" spread="2754"/>
                    <measurement group_id="O2" value="8840" spread="3678"/>
                    <measurement group_id="O3" value="-4322" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-24h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="789" spread="760"/>
                    <measurement group_id="O2" value="1518" spread="799"/>
                    <measurement group_id="O3" value="-950" spread="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-48h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1110" spread="1402"/>
                    <measurement group_id="O2" value="1650" spread="1474"/>
                    <measurement group_id="O3" value="-1810" spread="1001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-72h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1487" spread="2090"/>
                    <measurement group_id="O2" value="1726" spread="2176"/>
                    <measurement group_id="O3" value="-2536" spread="1731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-96h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1826" spread="2706"/>
                    <measurement group_id="O2" value="1751" spread="2867"/>
                    <measurement group_id="O3" value="-3297" spread="2471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC (0-168h)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2603" spread="4295"/>
                    <measurement group_id="O2" value="1316" spread="4998"/>
                    <measurement group_id="O3" value="-12308" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for All Participants</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for All Participants</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1425" spread="1297"/>
                    <measurement group_id="O2" value="6090" spread="3642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850" spread="3120"/>
                    <measurement group_id="O2" value="1678" spread="651"/>
                    <measurement group_id="O3" value="6979" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for All Participants</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for All Participants</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15540" spread="19437"/>
                    <measurement group_id="O2" value="13570" spread="6965"/>
                    <measurement group_id="O3" value="4615" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2015" spread="2855"/>
                    <measurement group_id="O2" value="12863" spread="16731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589" spread="17"/>
                    <measurement group_id="O2" value="4505" spread="2528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" spread="1540"/>
                    <measurement group_id="O2" value="1596" spread="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17079" spread="23224"/>
                    <measurement group_id="O2" value="12422" spread="7399"/>
                    <measurement group_id="O3" value="4615" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638" spread="566"/>
                    <measurement group_id="O2" value="16142" spread="17777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1842" spread="1451"/>
                    <measurement group_id="O2" value="8032" spread="4220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3210" spread="4052"/>
                    <measurement group_id="O2" value="1761" spread="566"/>
                    <measurement group_id="O3" value="6979" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma AUC0-∞ for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <description>AUC0-∞ is plasma area under the curve (AUC0-infinity)</description>
          <population>PK/PD</population>
          <units>mg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11951" spread="7374"/>
                    <measurement group_id="O2" value="13157" spread="6734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4769" spread="4128"/>
                    <measurement group_id="O2" value="12827" spread="18453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="33.1"/>
                    <measurement group_id="O2" value="53.9" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="29.6"/>
                    <measurement group_id="O2" value="9.7" spread="7.2"/>
                    <measurement group_id="O3" value="241.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.1" spread="292"/>
                    <measurement group_id="O2" value="103.6" spread="61.1"/>
                    <measurement group_id="O3" value="145" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="20.6"/>
                    <measurement group_id="O2" value="156.3" spread="245.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="1.7"/>
                    <measurement group_id="O2" value="41.4" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" spread="27.7"/>
                    <measurement group_id="O2" value="12.3" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.6" spread="317.4"/>
                    <measurement group_id="O2" value="96.5" spread="47.3"/>
                    <measurement group_id="O3" value="145" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="9.3"/>
                    <measurement group_id="O2" value="121.1" spread="102.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" spread="17.5"/>
                    <measurement group_id="O2" value="66.4" spread="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="37.7"/>
                    <measurement group_id="O2" value="7.1" spread="4.4"/>
                    <measurement group_id="O3" value="241.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Terminal Half-life (t1/2) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.1" spread="285.4"/>
                    <measurement group_id="O2" value="99.2" spread="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="2.2"/>
                    <measurement group_id="O2" value="185.6" spread="306.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.27"/>
                    <measurement group_id="O2" value="0.15" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.26"/>
                    <measurement group_id="O2" value="0.61" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.1"/>
                    <measurement group_id="O2" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.09"/>
                    <measurement group_id="O2" value="0.57" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.01"/>
                    <measurement group_id="O2" value="0.19" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.38"/>
                    <measurement group_id="O2" value="0.68" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.12"/>
                    <measurement group_id="O2" value="0.08" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0"/>
                    <measurement group_id="O2" value="0.19" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.35"/>
                    <measurement group_id="O2" value="0.09" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.23"/>
                    <measurement group_id="O2" value="0.54" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Clearance (CL) for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.02"/>
                    <measurement group_id="O2" value="0.08" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.07"/>
                    <measurement group_id="O2" value="1.01" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Volume of Distribution at Steady State (Vss) for apoA-I and PC After First Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Volume of Distribution at Steady State (Vss) for apoA-I and PC After First Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="64.7"/>
                    <measurement group_id="O2" value="7.4" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="4.4"/>
                    <measurement group_id="O2" value="14.4" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for All Participants</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for All Participants</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="16.6"/>
                    <measurement group_id="O2" value="9.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="7.5"/>
                    <measurement group_id="O2" value="58.3" spread="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.9"/>
                    <measurement group_id="O2" value="8.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="7.7"/>
                    <measurement group_id="O2" value="24.7" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Normal Renal Function</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="16.1"/>
                    <measurement group_id="O2" value="9.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="8.3"/>
                    <measurement group_id="O2" value="17" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after first infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vss for apoA-I and PC After First Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="78.1"/>
                    <measurement group_id="O2" value="6.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.3"/>
                    <measurement group_id="O2" value="4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
        <time_frame>Before first infusion (baseline) and for up to approximately 7 days after fourth infusion</time_frame>
        <population>PK/PD</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Vss for apoA-I and PC After Fourth Infusion for Participants With Mild Renal Impairment</title>
          <population>PK/PD</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>apoA-I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="21.3"/>
                    <measurement group_id="O2" value="9.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="8.2"/>
                    <measurement group_id="O2" value="83.1" spread="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With the Occurrence of Suspected Adverse Drug Reactions</title>
        <description>The overall percentage of subjects:&#xD;
with adverse events (AEs), including local tolerability events, that begin during or within 1 hour of an infusion; or&#xD;
with AEs considered to be causally related to the test product; or&#xD;
who experience an AE for which the incidence rate in an active treatment arm exceeds the exposure-adjusted incidence rate in the placebo arm by 30% or more, provided the difference in incidence rates is 1% or more.</description>
        <time_frame>From the start of first infusion, up to approximately Day 382</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With the Occurrence of Suspected Adverse Drug Reactions</title>
          <description>The overall percentage of subjects:&#xD;
with adverse events (AEs), including local tolerability events, that begin during or within 1 hour of an infusion; or&#xD;
with AEs considered to be causally related to the test product; or&#xD;
who experience an AE for which the incidence rate in an active treatment arm exceeds the exposure-adjusted incidence rate in the placebo arm by 30% or more, provided the difference in incidence rates is 1% or more.</description>
          <population>SP</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Any Adverse Event (AE)</title>
        <time_frame>From the start of first infusion, up to approximately Day 382</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Any Adverse Event (AE)</title>
          <population>SP</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6"/>
                    <measurement group_id="O2" value="51.4"/>
                    <measurement group_id="O3" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Experience Bleeding Events</title>
        <description>The number of subjects who experience bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria (Mehran et al, 2011)</description>
        <time_frame>From the start of first infusion, up to approximately Day 112</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Experience Bleeding Events</title>
          <description>The number of subjects who experience bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria (Mehran et al, 2011)</description>
          <population>SP</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="416"/>
                <count group_id="O3" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Antibodies to CSL112 and apoA-I</title>
        <time_frame>Before first infusion, up to approximately Day 112</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Antibodies to CSL112 and apoA-I</title>
          <population>SP</population>
          <units>Titer</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-CSL112 antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.14"/>
                    <measurement group_id="O2" value="0" spread="0.2"/>
                    <measurement group_id="O3" value="0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-apoA-I antibody</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.09"/>
                    <measurement group_id="O2" value="0" spread="0.14"/>
                    <measurement group_id="O3" value="0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Serology Results for IgG and IgM Antibodies to Parvovirus B19</title>
        <time_frame>Study Day 112</time_frame>
        <population>Serology population are a random subset of participants that was selected and had their samples tested for the presence of parvovirus B19.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Serology Results for IgG and IgM Antibodies to Parvovirus B19</title>
          <population>Serology population are a random subset of participants that was selected and had their samples tested for the presence of parvovirus B19.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Parvovirus B19 DNA in Serum</title>
        <time_frame>Study Day 112</time_frame>
        <population>Serology population</population>
        <group_list>
          <group group_id="O1">
            <title>CSL112 (2 g)</title>
            <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O2">
            <title>CSL112 (6 g)</title>
            <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.&#xD;
CSL112: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.&#xD;
Placebo: 0.9% weight/volume sodium chloride solution (ie, normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Parvovirus B19 DNA in Serum</title>
          <population>Serology population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 101 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 382 days for each participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety Lead-in [CSL112 (2 g)]</title>
          <description>In the safety lead-in, a small number of subjects (evenly stratified between subjects with normal renal function or mild renal impairment) were administered a single, 2 g infusion of CSL112.</description>
        </group>
        <group group_id="E2">
          <title>CSL112 (2 g)</title>
          <description>CSL112 (2 g) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.</description>
        </group>
        <group group_id="E3">
          <title>CSL112 (6 g)</title>
          <description>CSL112 (6 g) is to be administered as an IV infusion once weekly for 4 consecutive weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="415"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="416"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="415"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="415"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="416"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="416"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="415"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="416"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="415"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="416"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Registration Coordinator</name_or_title>
      <organization>CSLBehring</organization>
      <phone>610-878-4000</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

